Navigation Links
EntreMed Reports Fourth Quarter and Year-End 2011 Financial Results
Date:3/10/2012

ations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.  Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.

Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; our history of losses and expectation of incurring continued losses; the risk that our stockholders may not approve our recent financing transaction and our ability to repay the indebtedness incurred in connection with issuance and sale of the convertible notes if such notes are not converted into shares of common stock; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility of our common stock; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidate; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; declines in actual sales of Thalomid® resulting in reduced royalty payments; risks associated with our product candidates; any early-stage products under development; results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; the lack of success in the clinical development of any of our products; dependence on third parties; and risks relating to the commercialization, if any, of our  proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); and our ability to comp
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients
2. EntreMed Reports Fourth Quarter and Year-End 2010 Financial Results
3. EntreMed Reports Receipt of Third Quarter Royalty Payment
4. EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
5. EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
6. EntreMed to Present at the New York Society of Security Analysts Industry Conference
7. EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
8. EntreMed Reports Third Quarter 2008 Financial Results
9. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
10. EntreMed to Present at BioPartnering Europe Conference
11. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Md. , Sept. 16, 2014   ... biotechnology company developing novel anti-infective biologic and drug ... and diseases, announced today the completion of the Company,s ... which highlighted its irritable bowel syndrome (IBS) ... constipation-predominant IBS (C-IBS). In the keynote ...
(Date:9/16/2014)... , Sept. 16, 2014  Ascendis Pharma ... TransCon technology to address significant unmet medical needs, ... Phase 2 pediatric study to evaluate once-weekly TransCon ... or GHD.  The full interim results will be ... GRS and IGF Society, being held October 15-18, ...
(Date:9/15/2014)... NYHeat drives classical phase transitionsthink solid, liquid, ... when the temperature drops. If phase transitions ... quantum mechanics reigns, subtle fluctuations can dramatically ... the U.S. Department of Energy,s Brookhaven National ... this frigid landscape of absolute zero to ...
(Date:9/15/2014)... University have developed a technique for controlling the surface ... opening the door to a new generation of reconfigurable ... on the fact that the oxide "skin" of the ... acts as a surfactant, lowering the surface tension between ... used a liquid metal alloy of gallium and indium. ...
Breaking Biology Technology:Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Elusive quantum transformations found near absolute zero 2Elusive quantum transformations found near absolute zero 3Researchers control surface tension to manipulate liquid metals 2
... MINRAD,International, Inc. (Amex: BUF ) today announced that ... aggregate of $40.0 million of senior,secured convertible notes with ... The notes pay an 8% coupon, have a 3 ... The aggregate net,proceeds of the notes, after deducting the ...
... Biotech and pharma companies,are increasingly utilizing novel ... early in the development cycle to avoid ... and,Biotechnology News (GEN) ( http://www.genengnews.com/ ). By ... early, pharma also has the opportunity to ...
... Scientific,Corporation (NYSE: BSX ) announced today that ... issued its ruling in an,arbitration between the Company ... pursuant to the 2005 settlement agreement between,the companies, ... various U.S. and European patents held by Medinol. ...
Cached Biology Technology:MINRAD International, Inc. Announces $40.0 Million Private Placement 2MINRAD International, Inc. Announces $40.0 Million Private Placement 3Genetic Engineering and Biotechnology News (GEN) Reports on Early ADMET Use 2WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents 2WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents 3
(Date:9/16/2014)... interaction between viruses, bacteria, and their environment is ... collaboration between Matthew Sullivan, associate professor in the ... Biology and Steven Hallam from the University of ... are drivers of nutrient and energy cycles that ... is changing, so are the environments these bacteria ...
(Date:9/16/2014)... Schizophrenia is associated with increased rates and intensity of ... that the relationship between schizophrenia and smoking stems, in ... to self-medicate symptoms and cognitive impairment associated with the ... issue of Biological Psychiatry , sheds light on ... nicotine receptors in the brain was lower in schizophrenia ...
(Date:9/16/2014)... Proteins are responsible for practically all vital functions ... reactions, forward signals, transport particular substances and control ... that proteins do not function independently of each ... you examine the protein networks, you find many ... Falter-Braun from TUM,s Chair of Plant Systems Biology. ...
Breaking Biology News(10 mins):New research decodes virus-host interactions in ocean dead zones 2New research decodes virus-host interactions in ocean dead zones 3Smoking and schizophrenia linked by alterations in brain nicotine signals 2Good networkers make prime targets 2
... The Society of Interventional Radiology Foundation,s Discovery Campaign, ... invasive medicine into new areas of discovery, announced ... a manufacturer of medical devices, pharmaceuticals and medical ... and is a "Visionary" level supporter. ...
... In the waters off the North Carolina coast, historically-significant ... seafloor, a testament to a relatively unknown chapter in ... shipwrecks are not only important for their cultural value, ... fishes, invertebrates and algal species. Additionally, due to their ...
... by two teams of Army scientists and collaborators has identified ... virus infection. The findings, published online today in separate studies ... for combating one of the world,s most deadly viruses. ... high as 90 percent in humans. The virus is of ...
Cached Biology News:Single protein, key to ebola virus infection, could aid in drug design 2
... Cloning Kits are designed to speed up the ... PCR products, regardless of sequence or type of ... including those that are difficult to clone by ... unstable or code for potentially detrimental proteins can ...
... Blunt-Ended PCR Cloning Kit, 40 reactions. ... cloning of all PCR products with ... cloning approaches by offering consistently better ... 25-fold more positive clones.Amplicons generated by ...
Antibodies were affinity purified using epitopes specific to XLF immobilized on solid support....
... Clone/PAD: ZMD.460. Immunogen: Synthetic peptide ... human C35 protein (chromosome 17 open reading ... Specific for the C35 protein. On ... at ~15 kDa band. Reactivity: Human ...
Biology Products: